Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 58Terminated 18Withdrawn 6Unknown 6Recruiting 5Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 2Warts 1Neutropenia 1Lymphoma, Non-Hodgkin 1Leukopenia 1Leukemia, Myeloid, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × plerixafor × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

NCT05470491 2026-05-22

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
265 enrolled
Other hematologic neoplasm

Acquired Immunodeficiency Syndrome, Hematologic Neoplasms

NCT06158828 2026-05-05

ABCD-NK

Washington University School of Medicine

Phase 1/2 Recruiting
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Thomas Jefferson University

Phase 2 Recruiting
100 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡